Nimotuzumab is used in the treatment of head and neck cancer and cancer of colon and rectum. Nimotuzumab is a monoclonal antibody that specifically binds to receptors on cancer cells. Thus it flags the cancer cells for destruction by the body’s immune system.
BIOMAb EGFR® (Nimotuzumab) is also known by the brand names Theracim, Theraloc, etc., in different countries where it is approved.
BIOMAb EGFR® is currently approved for treatment of head and neck cancers in India, Cuba, Argentina, Colombia, Ivory Coast, Gabon, Ukraine, Peru, Vietnam and Sri Lanka; for glioma (pediatric and adult) in Cuba, Argentina, the Philippines, Myanmar, Mexico, Indonesia, Switzerland, Vietnam, Brazil and Ukraine; for nasopharyngeal cancer (a type of head and neck cancer) in China. It has been granted orphan drug status for Glioma in the USA and for Glioma and pancreatic cancer in Europe. A number of clinical trials are being conducted worldwide to evaluate the efficacy of this molecule in various other indications also like lung cancer, pancreatic cancer, cervical cancer etc.